Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Reveals Voice-Assistant Applications for Clinical Trials at ISPOR Annual European Congress


ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions
and services to the pharmaceutical, biotechnology and medical device
industries, today revealed proof-of-concept developments leveraging
Voice Assistant technology to support patients in clinical trials.

Responding to the drive to leverage technology to make trial
participation simpler, more convenient and more patient-centric, ICON
will be demonstrating early work using the Amazon Echo Voice Assistant
platform to enhance interactions with patients enrolled into clinical
trials, at the ISPOR 20th Annual European Congress, Glasgow, Scotland on
Wednesday 8th November 2017.

ICON's proof-of-concept application leverages a Voice Assistant to
deliver a patient-reported outcome instrument and collect patient
responses that may have application in future clinical trials. Operating
in multiple languages, initial informal testing of the application,
which is launched using the command "Alexa, complete my diary", has
indicated that the platform is able to operate robustly with multiple
users and languages with minimal training.

"The development of conversational applications may provide an
effective way of interacting with patients in an engaging manner in
future clinical trials,
" commented Tom O'Leary, CIO, ICON plc. "Our
industry already has experience of using voice-delivered
patient-reported outcome instruments using telephone-based IVR systems.

As Voice Assistant technology becomes increasingly adopted, it
provides the opportunity to deliver interactive and engaging approaches
in areas such as patient education, trial consent and the collection of
patient-reported outcomes data..

It is predicted that by 2020, 30% of web browsing sessions will be done
using Voice Assistants or Virtual Reality [1]. This is further
demonstrated by the rapid increase in sales of voice-enabled devices
such as Amazon Echo and Google Home which are predicted to rise 130%
this year in the US [2].

ICON continues to focus on the factors that are critical to transforming
trials for future success, including exploring how to best leverage new
technology in novel ways to provide rapid access to, and analysis of,
high-quality data to speed and improve decision making in clinical
trials. This work is one part of the innovation and research ICON and
Mapi experts will present at the ISPOR
Annual European Congress
in Glasgow, comprising over 50 posters,
short courses and workshops.

About ICON plc

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees.

Further information is available at

[1] Gartner (2017). Gartner's Top 10 Strategic Predictions for 2017 and
Beyond: Surviving the Storm Winds of Digital Disruption.

[2] eMarketer (2017).

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!